HDAC1 inhibitors such as MS-275 have already been tested in many clinical trials for anti-cancer treatment 23, 46, thus they could be clinically effective tools to enhance β-cell function through triggering serotonin production, as supported by amplified insulin response in MS-275-injected mice. Here, HDAC1 is linked to cancer.